Piper Jaffray Raises Price Target on Boston Scientific (BSX) Following FDA Approval of BP-DES
Tweet Send to a Friend
Piper Jaffray reiterated an Overweight rating on Boston Scientific (NYSE: BSX), and raised the price target to $22.50 (from $21.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
